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The position of the catheters relative to the tumour bed was 
measured in CT. 
Results: With sole US guidance, seven out of 10 catheters passed 
through the tumour bed. The catheter spacing was inconsistent 
and the desired goal of two rows of five equally-spaced catheters 
was not precisely achieved, with a mean spacing of 1.0 cm with 
0.7 - 1.9 cm range. Under combined EMT-US guidance, nine out 
of 10 catheters passed through the tumour bed, yielding two 
rows of five catheters with more consistent spacing, with a mean 
spacing of 1.0 cm with 0.8-1.2 cm range. 
Conclusions: This phantom experiment suggests that combined 
EMT-US guidance can help achieve consistent catheter spacing 
over the tumour bed. These results are preliminary, and a trial 
of the method is now being conducted to validate our results. 
Additional research is being conducted to translate the proposed 
navigation technique to patient trials. 
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Purpose: Endobronchial metastasis originating from primary 
cancers outside the lung are rare in comparison with 
parenchymal metastasis. External beam radiotherapy (EBRT) is 
often attempted for control of cough, hemoptysis, chest pain and 
dyspnea with variable effectiveness and potential toxicities. 
There are also limitations to re-treatment with EBRT if symptoms 
recur. Documented experience in the use of brachytherapy for 
these patients is very limited in the literature. We report a 
cohort of patients with endobronchial metastasis treated with 
high-dose rate (HDR) brachytherapy at our center. 
Methods and Materials: A prospective database was created 
from 2006-2015 including demographic, treatment and outcome 
data. Patients with endobronchial metastasis from any primary 
site outside the lung who received one or more high-dose rate 
brachytherapy treatments with iridium-192 were included. 
Cough, dyspnea, chest pain and hemoptysis were assessed and 
graded by the primary medical team as absent (0), mild (1), 
moderate (2), significant (3), and severe (4) at the time of initial 
consult and in follow up. The duration of symptom improvement 
and re-expansion of the lung documented on imaging were 
analyzed using Kaplan-Meier curves.  
Results: Thirty-five patients with endobronchial metastasis were 
identified (14 GIT, five breast, three each of 
sarcoma, lymphoma, melanoma, renal cell, two head and 
neck, one cervix and one testicle). The majority of patients 
received three fractions of 700 cGy, and 15 patients had 
received EBRT to the lung beforehand and four afterwards. 
Median symptom-free survival was 67 days and overall 
survival was 117 days. Of patients reporting the presence 
of symptoms at baseline, improvement in cough was 
documented in 75.0 % (21/28), hemoptysis in 76.4% (13/18), 
pain in 64.3% (9/14) and dyspnea in 60.0% (18/30) for a median 
of three, three, three and six months respectively. Absent to 
mild cough (n = 8), hemoptysis (n = 17), pain (n = 21), and 
dyspnea (n = 6) scores were maintained for median periods of 
two, three and four months respectively. Of the 22 patients 
who had subsequent chest imaging, re-expansion was 
documented in 32%. There were no significant toxicities 
reported. 
Conclusions: Brachytherapy appears effective in achieving 
durable symptom control of cough hemoptysis and dyspnea in 
patients with metastatic disease located in the bronchus. It can 
be used in combination with or as an alternative to external 
beam radiotherapy, and should be considered routinely where 
available in this patient population. Further studies are required 
to better characterize expected symptom improvement and lung 
re-expansion rates. 
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Purpose: Endobronchial complications of primary and metastatic 
lung malignancy contribute to considerable patient morbidity 
and adversely affect quality-of-life with symptoms of dyspnea 
and hemoptysis. Endobronchial High-Dose Rate (HDR) 
Brachytherapy is an efficacious treatment strategy indicated for 
large obstructing endobronchial lesions not amenable for surgical 
resection, combination treatment with external beam 
radiotherapy for potentially improved local control and for the 
palliation of symptoms in the re-treatment setting. The purpose 
of this study was to explore the clinical features and outcomes 
in a consecutive series of patients treated for malignant 
endobronchial obstruction at a single institution. 
Methods and Materials: A retrospective analysis was performed 
on all consecutive patients treated at the Cancer Centre of 
Southeastern Ontario with endobronchial HDR Brachytherapy 
between November 2012 and March 2015. The demographic and 
clinical characteristics were collected and overall survival and 
symptomatic progression-free survival are reported. 
Results: Twenty-eight consecutively treated patients (17 male 
and 11 female) were identified for review. The average age at 
the time of treatment was 69.12 years. The majority of patients 
had a histopathological diagnosis of lung cancer (n = 21 non-small 
cell lung cancer, n = 1 small cell lung cancer) while the 
remainder (n = 6) had metastatic disease from other primaries. 
Fifteen patients had metastatic disease at presentation and nine 
were treated with systemic therapy prior to brachytherapy. The 
major indication for treatment included dyspnea (n = 18) and 
hemoptysis (n = 10) with 12 patients identified to have complete 
bronchial occlusion by bronchoscopy. Two patients were treated 
in a critical care setting and discharged home with stabilization 
of symptoms. The median overall survival for the group was 17.58 
weeks while the median symptomatic progression-free survival 
was 9.82 weeks. 
Conclusions: Endobronchial HDR brachytherapy remains an 
efficacious treatment strategy for patients presenting with 
malignant bronchial occlusion causing dyspnea and/or 
hemoptysis. Our experience demonstrates that carefully-
selected patients can experience effective palliation of 
symptoms despite an overall poor prognosis for the group. While 
limited, our experience also demonstrates that some patients 
with massive-hemoptysis or respiratory failure may benefit from 
treatment in the hands of a skilled brachytherapy team. 
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Purpose: The dosimetry of trans-perineal interstitial 
brachytherapy (ISBT) treatment of gynecological malignancies 
can be significantly affected by the presence of rectal gas. This 
study evaluates the impact of using a rectal tube on dosimetric 
factors. 
Methods and Materials: Twenty-nine patients treated between 
August and December 2015 at our institution were included in a 
prospective registry trial. Data on the use of a rectal tube and 
dosimetric parameters were collected. Rectal volume, maximum 
dose to 2 cc of the rectum contour (D2cc) and the minimum dose 
to 90% of the high-risk clinical target volume (HR-CTV D90) was 
compared using a t-test for the rectal tube and no rectal tube 
cohorts. The rectal volume was measured from 1cm above and 
